Our strength is in our breadth

  • HOME
  • MESSAGE FROM THE CHAIR
  • WELCOME
  • JOIN US
    • Join Us
    • Membership options
  • ABOUT US
    • About Us
    • Our Board
    • Our Ambassadors
    • Our Members
    • Foundation Partners
    • Collaborative Partners
    • What are we up to
    • Why we do what we do
    • AMCA Opinion
  • COMPASS
  • CONTACT US
  • CALENDAR 2022
  • CANNABIZ
  • DRUG DRIVING
  • INFORMATION FOR PATIENTS
  • USEFUL LINKS
  • LINKS TO GOVERNMENT SITES
  • MEMBERS' PRIVATE PAGES
    • AMCA AGM
    • AMCA Interest Groups
    • Offers for AMCA members
    • FRESHLEAF BLOG
    • TGA updates
    • Submissions
    • Q&A
    • Clinical papers
  • More
    • HOME
    • MESSAGE FROM THE CHAIR
    • WELCOME
    • JOIN US
      • Join Us
      • Membership options
    • ABOUT US
      • About Us
      • Our Board
      • Our Ambassadors
      • Our Members
      • Foundation Partners
      • Collaborative Partners
      • What are we up to
      • Why we do what we do
      • AMCA Opinion
    • COMPASS
    • CONTACT US
    • CALENDAR 2022
    • CANNABIZ
    • DRUG DRIVING
    • INFORMATION FOR PATIENTS
    • USEFUL LINKS
    • LINKS TO GOVERNMENT SITES
    • MEMBERS' PRIVATE PAGES
      • AMCA AGM
      • AMCA Interest Groups
      • Offers for AMCA members
      • FRESHLEAF BLOG
      • TGA updates
      • Submissions
      • Q&A
      • Clinical papers
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

Signed in as:

filler@godaddy.com

  • HOME
  • MESSAGE FROM THE CHAIR
  • WELCOME
  • JOIN US
  • ABOUT US
  • COMPASS
  • CONTACT US
  • CALENDAR 2022
  • CANNABIZ
  • DRUG DRIVING
  • INFORMATION FOR PATIENTS
  • USEFUL LINKS
  • LINKS TO GOVERNMENT SITES
  • MEMBERS' PRIVATE PAGES

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

PDF Viewer

Download PDF

new study from the University of Sydney’s Lambert Initiative

Are blood and oral fluid Δ9-tetrahydrocannabinol (THC) and metabolite concentrations related to impairment? A meta-regression analysis


 

Highlights:


  • THC-related biomarkers were associated with impairment in occasional cannabis users.


  • However, most of these ‘biomarker–performance’ relationships were ‘weak’ in strength.


  • THC-related biomarkers were not associated with impairment in regular cannabis users.


  • THC-related biomarkers are relatively poor indicators of cannabis-induced impairment.

Published in Neuroscience & Biobehavioral Reviews

Click here to access online

International JOURNAL OF DRUG POLICY (Volume 97, Nov 2021)

Medicinal cannabis and driving: the intersection of health and road safety policy

Background

Recent shifting attitudes towards the medical use of cannabis has seen legal access pathways established in many jurisdictions in North America, Europe and Australasia. However, the positioning of cannabis as a legitimate medical product produces some tensions with other regulatory frameworks. A notable example of this is the so-called ‘zero tolerance’ drug driving legal frameworks, which criminalise the presence of THC (tetrahydrocannabinol) in a driver's bodily fluids irrespective of impairment. Here we undertake an analysis of this policy issue based on a case study of the introduction of medicinal cannabis in Australia.


Conclusion

We conclude that in medical-only access models there is little evidence to justify the differential treatment of medicinal cannabis patients, compared with those taking other prescription medications with potentially impairing effects.


Click picture to see full abstract

  • COMPASS
  • CONTACT US
  • CALENDAR 2022
  • CANNABIZ
  • DRUG DRIVING
  • INFORMATION FOR PATIENTS
  • AMCA Interest Groups
  • Q&A

Australian Medicinal Cannabis Association

AMCA Platinum members: ANTG and MiDispensary

Copyright © 2022 Australian Medicinal Cannabis Association - All Rights Reserved.